Nuwamba 2021: The first clinical trial of South Korea’s homegrown next-generation chimeric antigen receptor T (CAR-T) cell therapy, which is designed to circumvent immune checkpoint signals, has recently gotten under way.
Cibiyar Kimiyya da Fasaha ta Koriya ta Koriya (KAIST) ta sanar a ranar Laraba cewa a halin yanzu ana gudanar da gwajin gwaji na kashi 1b na maganin tantanin halitta na CAR-T a Cibiyar Kiwon Lafiya ta Samsung da ke Seoul. Ana gudanar da gwajin tare da majinyatan Koriya 10 waɗanda suka sake dawowa kuma suka watsar da babban lymphoma cell B. An tura haƙƙin tallace-tallace na bututun daga jami'a zuwa kamfanin Curocell, wanda Farfesa Kim Chan-hyuk ya kafa. Curocell ne ke kula da shirin ci gaban asibiti na mai juyin juya hali immunotherapy.
In addition, a Phase 2 gwajin gwaji involving seventy participants is going to take place the following year to assess how safe and effective the investigational medication is.
The acronym CAR T, which stands for chimeric antigen receptor T, is frequently referred to as a miracle cure. This is due to the fact that studies conducted in other countries on terminal blood cancer patients demonstrated that the therapy had a therapeutic effect of more than 80 percent. T cells from a patient are taken from the patient’s blood, genetically enhanced to make them more effective, and then reintroduced to the patient so that they can continue to fight and destroy cancer cells inside the patient’s body.
The research team that was led by Professor Kim of the Department of Biomedical Engineering at the KAIST confirmed an improved anticancer efficacy of CAR-T cells in mice with leukaemia and lymphoma. This was achieved by simultaneously inhibiting programmed cell death protein 1 (PD-1) and T-cell immunoglobulin and ITIM domain (TIGIT), both of which are known to disturb the function of T cells. According to Professor Lee Young-ho, a post-doctoral researcher at KAIST and the first author of the animal model study, this dual blockade of PD-1 and TIGIT is a novel strategy to overcome the immunosuppression of existing CAR-T cells. This strategy was discovered by Prof. Lee Young-ho.
Kuna so karanta: CAR T-Cell far a Koriya
An gabatar da sakamakon binciken a cikin wata kasida da aka buga a kan layi a cikin Oktoba na Ƙwararrun Kwayoyin cuta.
